Accessibility Menu
Shionogi & logo

Shionogi &(OTC) SGIOF

Market Cap$15.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+322%
5 Year+2%
1 Year+9%
1 Month+1%
$17.90
+0.00%
+0.00Today
Shionogi & last closing stock price
MetricPriceDate
Last closeUSD 17.902026-08-10
Shionogi & stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.58%USD 17.452026-08-03
1 month+0.51%USD 17.812026-07-10
3 month+1.24%USD 17.682026-05-12
Year to date+19.11%USD 15.032025-12-30
1 year+9.18%USD 16.392025-07-30
3 year+42.85%USD 12.532023-08-10
5 year+1.61%USD 17.622021-08-11
Since inception+321.67%USD 4.252003-06-30

Shionogi & Financials at a Glance

Market Cap

$15.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥564.65B

Net Income (TTM)

¥263.79B

EPS (TTM)

$1.99

P/E Ratio

8.98

Dividend

$0.46

Beta (Volatility)

0.21 (Low)

Price

$17.90

Volume

8

Open

$18.45

Previous Close

$17.90

Daily Range

$17.90 - $18.45

52-Week Range

$14.25 - $26.00

Estimated Earnings Date

Oct 29, 2026

SGIOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shionogi &

Shionogi & Co., Ltd. is a Japanese pharmaceutical company dedicated to the entire lifecycle of drug development, from research to production. The company specializes in innovative therapies and diagnostic tools, focusing on addressing unmet medical needs across various therapeutic areas.

Products and Services
  • Fetroja, a treatment for multidrug-resistant bacterial infections
  • Xofluza, an antiviral medication for influenza
  • Tivicay, used in HIV management
Growth Outlook
  • Strong pipeline with multiple investigational therapies for chronic conditions
  • Recent collaborations with academic institutions enhance research capabilities
  • Focus on COVID-19 therapeutics positions the company for future growth
Financial Highlights
  • Recent quarterly revenue of 139.87 billion JPY, showcasing robust performance
  • Net income margin of 33.77% indicates strong profitability
  • TTM P/E ratio of 12.04 suggests attractive valuation compared to industry peers
Shionogi & Co., Ltd. has established itself as a key player in the pharmaceutical industry, with a diverse portfolio of products aimed at treating various medical conditions. The company's commitment to research and development is evident in its extensive pipeline, which includes treatments for chronic pain, central nervous system disorders, and oncology. Recent financial performance highlights a strong revenue base and profitability, making it an intriguing option for investors interested in the healthcare sector. The company's strategic collaborations and focus on innovative therapies further enhance its growth potential in a competitive market.
AI Generated • Jul 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

6,223

CEO

Isao Teshirogi, PhD

Website

www.shionogi.com

Headquarters

Osaka, OS 541-0045, JP

SGIOF Financials

Key Financial Metrics (TTM)

Gross Margin

78.27%

Operating Margin

29.27%

Net Income Margin

46.79%

Return on Equity

16.46%

Return on Capital

6.81%

Return on Assets

9.92%

Earnings Yield

11.14%

Dividend Yield

2.58%

Payout Ratio

22.97%

Stock Overview

Market Cap

$15.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

850.98M

Volume

8

Avg. Volume

1.15K

Financials (TTM)

Gross Profit

¥442.14B

Operating Income

¥165.38B

EBITDA

¥259.44B

Operating Cash Flow

¥216.64B

Capital Expenditure

-¥14.60B

Free Cash Flow

¥202.04B

Cash & ST Invst.

¥296.78B

Total Debt

¥679.18B

Shionogi & Performance Analysis

Shionogi & annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 3,149,822,8305.6%
20242024-03-31JPY 3,012,746,258-4.4%
20252025-03-31JPY 2,874,824,175-4.6%
20262026-03-31JPY 3,315,880,85915.3%
Shionogi & sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3014.5%
Q32025-12-3128.8%
Q42026-03-31-5.4%
Q12026-06-3015.9%
Shionogi & annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 1.5336.1%
20242024-03-31JPY 1.29-15.7%
20252025-03-31JPY 1.311.9%
20262026-03-31JPY 1.6021.8%
Shionogi & sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3014.5%
Q32025-12-3166.8%
Q42026-03-31-36.3%
Q12026-06-30105.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥162.13B

+61.7%

Gross Profit

¥115.85B

+32.5%

Gross Margin

71.45%

N/A

Market Cap

$15.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.45M

N/A

Employees

6,223

N/A

Net Income

¥96.99B

+145.3%

EBITDA

¥60.19B

+11.6%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥296.78B

+16.5%

Total Debt

¥679.18B

+3031.6%

Accounts Receivable

¥171.93B

+49.9%

Inventory

¥108.17B

+52.6%

Long Term Debt

¥18.16B

+0.4%

Short Term Debt

¥661.02B

+18145.4%

Return on Assets

9.92%

N/A

Return on Invested Capital

8.96%

N/A

Free Cash Flow

¥38.23B

+4.1%

Operating Cash Flow

¥42.80B

+3.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FMCQFFresenius Medical Care AG
$51.44+0.00%
BIOVFSwedish Orphan Biovitrum AB (publ)
$48.21+0.00%
SONVYSonova Holding AG
$59.03+0.72%
CHJTFCSPC Pharmaceutical Group Limited
$1.07+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.10+0.08%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.72+0.01%
ONDSOndas
$9.11+0.02%
SPCXSpace Exploration Technologies
$140.07-0.01%

Questions About SGIOF

What is the current price of Shionogi &?

Shionogi & is trading at $17.90 per share.

What is the 52-week range for Shionogi &?

Over the past 52 weeks, Shionogi & has traded between $14.25 and $26.00.

How much debt does Shionogi & have?

As of the most recent reporting period, Shionogi & reported total debt of ¥4.21B.

How much cash does Shionogi & have on hand?

Shionogi & reported ¥1.84B in cash and cash equivalents in its most recent financial results.

What is Shionogi &’s dividend yield?

Shionogi & currently has a dividend yield of 2.58%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services